COVID-19

  • Event
    Trial Innovation Network Logo
    Date
    -
    Recruitment in the Time of COVID-19: Single and Multisite Study Strategies Using ResearchMatch
  • Consortium News
    Doctor treating patient
    Georgia CTSA MSCR Trainee Receives Artemis Award for Work with Ebola Survivors
  • Consortium News
    NYU PIs
    COMBATCOVID (Consortium for Multisite Biomedical Analytics and Trials on COVID-19)
  • Consortium News
    person holding iphone
    Creating customized approaches for communities in the fight against COVID-19
  • Consortium News
    Illustration depicting use of network, cellular and other technology to improve surge ICU capacity. Illustration by Emma Vought
    MUSC team is one of nine chosen by U.S. Army to build a prototype for increasing ICU surge capacity during COVID-19
  • Event
    HAI Stanford
    Date
    -
    Collected & Augmented Intelligence Against COVID-19
  • Consortium News
    Image showing layers of city building overlaid with multi-colored outlines of figures of people connected by lines.
    How Massachusetts Became First in Nation to Contact Trace
  • Consortium News
    VRIP interns attend their first virtual seminar meeting with Laura Contreras-Ruiz of Dana-Farber Cancer Institute and Jessica St. Louis of Harvard Catalyst's Diversity Inclusion program.
    Outside the Lab, Inside Harvard
  • Resource
    National COVID Cohort Collaborative (N3C)
    National COVID Cohort Collaborative (N3C) Communications Guidance
  • The PI and the NYU Grossman School of Medicine (NYUGSOM) Study Team will be responsible for recruiting, randomizing, and following 200 hospitalized patients with COVID-19 from recruitment to 90-day follow-up as per the study protocol. In addition, NYUGSOM will also manage the IND and regulatory reporting for the study. NYUGSOM will additionally create and manage the study database and provide access to the Albert Einstein College of Medicine site. The electronic data capture system will handle all data and safety monitoring across the two institutions.

    This randomized, blinded phase 2 adaptive trial will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms between 3 and 7 days after the onset of symptoms OR within 3 days of hospitalization. A total of 300 eligible subjects will be randomized in Stage 1 of the trial to a 1:1 ratio to receive either convalescent plasma from people who have recovered from Covid-2 containing antibodies to SARS-CoV-2 or control (saline solution). Subsequent Stages of the trial will be defined after conclusions from the previous Stage.
    Target Population
    Hospitalized Patients with COVID-19
    Primary Investigator
    Study Type
    Treatments and Interventions
    Clinicaltrials.gov Status
    Submitted to clinicaltrials.gov
    ClinicalTrials.gov Identifier
    NCT04364737
    Current Study Status
    Recruiting
    Current Study Phase
    Phase 2
    Clinical Trial Network Utilization
    Not Sure
    Accrual Target Number
    300
    CTSA Support
    Yes
  • Mikes Blog

    National COVID Cohort Collaborative (N3C)

  • Consortium News
    Washington University School of Medicine postdoctoral researchers Pallavi Chandra, PhD and Ekansh Mittal, PhD
    Washington University’s Institute of Clinical and Translational Sciences supports effort to screen potential COVID-19 antiviral drugs
  • Consortium News
    ICTS COVID-19 Research Funding Program Awardees
    The Foundation for Barnes-Jewish Hospital and ICTS Announce COVID-19 Research Funding Program Awardees
  • Consortium News
    Eric C. Landsness, MD, PhD and Shannon C. Agner, MD, PhD (left to right)
    Washington University Investigators Utilize ICTS Structure and Resources to Advance COVID-19 Research
  • Consortium News
    Yuefang Huang, senior research technician at Washington University School of Medicine in St. Louis
    COVID-19 antibody tests evaluated as diagnostic test in low-resource settings
  • Consortium News
    headshot of Albhaisi over image of test tubes being labelled
    VCU Wright Center helps fund and build a biobank to fight COVID-19
  • Consortium News
    N3C: Partnership and Governance for COVID-19 Research
  • Consortium News
    headshot of Steven Woolf
    VCU Wright Center researcher publishes COVID-19 excess mortality data
  • Event
    National Institutes of Health
    Date
    -
    COVID Open Science Collaborative Analytics Platform: National COVID Cohort Collaborative (N3C)
  • Consortium News
    TraCS SECURE-IBD Logo
    SECURE-IBD Provides Answers During Uncertain Times
  • Consortium News
    Kappelman Receives Award From Crohn's & Colitis Foundation
  • Consortium News
    scientist sitting in front of a laminar flow biological safety cabinet
    UAMS-Developed High-Accuracy COVID-19 Antibody Testing Begins in Arkansas
  • Event
    Duke, UNC, and Wake Forest Coronavirus Collaboration
    Date
    -
    Research Resilience in the Age of COVID-19: Insights from Sponsors and Investigators
  • Consortium News
    puzzle and hands
    COMBATCOVID (Consortium for Multisite Biomedical Analytics and Trials on COVID-19)
  • Consortium News
    screenshot
    Improved Sample Size Calculator Website & New Calculators for Your Research
  • Event
    CD2H-teal
    Date
    -
    Healthcare Open Terminology (HOT) Ecosystem Community Meeting
  • Consortium News
    CDRC
    C-Path Launches CURE Drug Repurposing Collaboratory to Accelerate Identification of New Uses of Existing Drugs to Treat Infectious Diseases, Including COVID-19
  • Event
    COV-IRT Logo
    Date
    -
    COV-IRT 2nd Annual Virtual Symposium
  • Resource
    National COVID Cohort Collaborative (N3C)
    NCATS N3C Media Toolkit
  • CLIC News
    digital picture of the US over a digital plane
    National COVID Cohort Collaborative (N3C) Stakeholder Toolkit